GleamWall
中文EN

ODYY Odyssey Health, Inc.

Surgical & Medical Instruments & Apparatus · OTC · SEC CIK 1626644 · Fiscal year ends 07/31

Financial factors as of 2026-07-31 (2026Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-228.8%
TTM EPS YoY-150.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-5,799.8%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets8,303.6%
Debt / equity—
Current ratio0.01x
Interest coverage-0.58x

Cash quality & payout

Operating cash flow / net income0.18x
Accruals ratio-4,740.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q4*2026-07-312026Q32026-04-302026Q22026-01-312026Q12025-10-312025Q4*2025-07-312025Q32025-04-302025Q22025-01-312025Q12024-10-31
Income statement
Revenue————————
R&D expense————$0$0$0$0
SG&A expense$130,307$297,554$181,942$303,190$264,077$129,055$156,593$579,427
Operating income-$130,307-$297,554-$181,942-$303,190-$155,678-$129,055-$156,593-$579,427
Interest expense$547,500$527,551$412,429$95,336$58,905$61,395$63,431$68,781
Net income-$2.41M$765,890-$3.60M-$483,447-$251,916-$251,743-$220,126-$1.02M
EBITDA—————-$129,055-$156,593-$579,427
EPS (basic)—0.01-0.030.00—0.000.00-0.01
EPS (diluted)—0.01-0.030.00—0.000.00-0.01
Weighted avg. shares (diluted)—186.67M107.85M106.04M—104.71M104.71M104.71M
Balance sheet
Cash & equivalents$122,361$297,806$616,327$25,586$19,084$3,186$7,187$53,865
Current assets$147,859$373,779$721,304$143,622$49,723$67,359$108,361$182,540
Total assets$147,859$373,779$721,304$143,622$49,723$164,508$266,866$341,045
Current liabilities$12.28M$10.12M$11.32M$7.30M$7.00M$6.87M$6.73M$6.62M
Total liabilities$12.28M$10.12M$11.32M$7.30M$7.00M-$6.54M$6.73M$6.62M
Shareholders' equity-$12.13M-$9.75M-$10.60M-$7.16M-$6.95M$6.70M-$6.46M-$6.28M
Shares outstanding105.97M100.97M99.85M99.85M96.71M96.71M96.71M96.71M
Cash flow statement
Operating cash flow-$159,580-$318,521-$284,259-$283,998-$48,199-$4,001-$46,678-$248,514
Investing cash flow————$69,787$0——
Financing cash flow-$15,865$0$875,000$290,500-$5,690$0$0$300,000
Depreciation & amortization—————$0$0$0
Stock-based compensation$5,408$0$0$0$0$11,781$36,131$60,487

Free plan shows the latest 8 periods; Pro shows all 48 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.